Skip to search formSkip to main contentSkip to account menu

trabectedin

A tetrahydroisoquinoline alkaloid isolated from the marine tunicate Ecteinascidia turbinata with potential antineoplastic activity. Binding to the… 
National Institutes of Health

Related topics

Related topics

9 relations
Alkylating Activity [MoA]NCIt Antineoplastic Agent Terminologytrabectedin 1 MG Injection [Yondelis]

Broader (3)

Antineoplastic Agents, AlkylatingDioxolesTetrahydroisoquinolines

Narrower (3)

Ecteinascidin 743NSC 684766Yondelis

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2019
2019
SAINT: Results of a phase 1/2 study of safety/efficacy using safe amounts of ipilimumab, nivolumab, and trabectedin as first-line treatment of advanced soft tissue sarcoma.
11016 Background: Sarcoma cells are most immunogenic earlier in the disease course and prior to treatment when the immune system… 
Review
2015
Review
2015
Beyond clinical trials in advanced soft tissue sarcoma: what to expect from trabectedin treatment? Foreword.
*Department of Interdisciplinary Oncology, HELIOS Klinikum Berlin-Buch, Berlin, Germany; Tel.: +49 30 9401 54801; peter.reichardt… 
2014
2014
Association between the HER 2 Ile 655 Val polymorphism and response to trastuzumab in women with operable primary breast cancer
1979; 35: 549–556. 19. Lan KKG, DeMets DL. Discrete sequential boundaries for clinical trials. Biometrika 1983; 70: 659–663. 20… 
2012
2012
Advances in epithelial ovarian cancer therapy.
Advanced epithelial ovarian carcinoma has a dismal prognosis. Notwithstanding the good initial response to primary therapy, 75… 
2011
2011
TRABECTEDIN: A NOVEL MOLECULAR THERAPEUTIC IN CANCER
Nature has been instrumental as a source for therapeutics. Despite the fact that we live in an oceanic planet, a number of… 
2010
2010
eview of Trabectedin ( ET-743 ) : A Unique Ther hanism of Action zio
ownload ectedin (ET-743) is a marine alkaloid isolated from the Caribbean tunicate Ecteinascidia turbinata, with ical structure… 
2010
2010
Outcomes of patients (pts) with advanced soft-tissue sarcomas (STS) treated in clinical trials (CTs) versus expanded access programs (EAPs): A decade of experience with single-agent trabectedin (Tr).
10029 Background: Pts who do not qualify for CTs may enter EAPs when available, allowing treatment with new agents prior to… 
2010
2010
A phase II trial of trabectedin (T) in patients (pts) with HER2-positive and BRCA1/2 germ-line-mutated metastatic breast cancer (MBC).
1038 Background: Single agent T has shown activity in soft tissue sarcoma (STS), ovarian, and breast carcinoma. The European… 
2007
2007
Fetal bovine serum, but not human serum, inhibits the in vitro cytotoxicity of ET-743 (Yondelis, trabectedin)
a 80The first studies to assess the biological activity of new anticancer drugs are usually done on tumor cells growing in vitro… 
2005
2005
Trabectedin (YondelisTM, formerly ET-743), a mass balance study in patients with advanced cancer
Trabectedin (YondelisTM, formerly ET-743) is an anti-cancer drug currently undergoing phase II development. Despite extensive…